

EBV Viral Load in Tumor Cells Did Not Predict Tumor Extensiveness in Nasopharyngeal Cancer

Soehartati A Gondhowiardjo

Faculty of Medicine, Universitas Indonesia

Handoko Handoko (✉ handoko.asia@gmail.com)

Faculty of Medicine, Universitas Indonesia <https://orcid.org/0000-0002-2834-9090>

Marlinda Adham

Faculty of Medicine, Universitas Indonesia

Lisnawati Rachmadi

Faculty of Medicine, Universitas Indonesia

Henry Kodrat

Faculty of Medicine, Universitas Indonesia

Demak Lumban Tobing

Rumah Sakit Dharmais Pusat Kanker Nasional

I Made Haryoga

Faculty of Medicine, Universitas Indonesia

Agustinus Gatot Dwiyo

Faculty of Medicine, Universitas Indonesia

Yoseph Adi Kristian

Faculty of Medicine, Universitas Indonesia

Tiara Bunga Mayang Permata

Faculty of Medicine, Universitas Indonesia

Takahiro Oike

Gunma University Graduate School of Medicine

Research article

Keywords: Epstein Barr Virus; viral load; nasopharyngeal cancer; tumor extensiveness; prognosis

Posted Date: February 11th, 2020

DOI: <https://doi.org/10.21203/rs.2.23244/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background:

Nasopharyngeal cancer is commonly associated with EBV infection, especially the undifferentiated non keratinized histology. EBV DNA quantification through nasopharyngeal brushing was previously reported not related with disease stages. This study aimed to reinvestigate relationship of EBV viral load in tumor tissue with tumor extensiveness by more accurate EBV DNA quantification through microscopically confirmed tumor cells from nasopharyngeal biopsy.

Method:

The specimens for EBV DNA quantification was derived from histopathology slides which was pre-treated following QIASymphony® SP Protocol for tissue DNA extraction. Then the extracted DNA underwent real time Polymerase Chain Reaction (RT-PCR) using artus® EBV RG PCR Kit for EBV DNA quantification. The tumor volume was determined by delineating gross tumor based on 3D imaging of the patient's nasopharynx.

Result:

Twenty-four subjects were included in this study. All subjects were stage III and above with more males (75%) than females. EBV viral load in tumor cells were found to have no correlation with tumor volume both in local and nodal. The median local tumor volume was $81.3 \text{ cm}^3 \pm 80 \text{ cm}^3$. The median EBV viral load in tumor cells was $95,644.8 \text{ copies}/100\text{ng of DNA} \pm 224,758.4 \text{ copies}/100\text{ng of DNA}$. The median nodal or regional tumor volume was $35.7 \text{ cm}^3 \pm 73.63 \text{ cm}^3$.

Conclusion:

EBV viral load from tumor cells from nasopharyngeal biopsy has no relationship with tumor extensiveness in nasopharyngeal cancer. The presence and number of EBV in tumor cells did not translate into larger or smaller tumor. The EBV viral proteins and RNAs were perhaps more likely to confer some prognostic information due to the facts that those molecules were related with carcinogenesis.

Introduction

Development of nasopharyngeal cancer is very much related with Epstein Barr Virus (EBV).¹ EBV was found in approximately all nasopharyngeal cancer with undifferentiated non keratinized histology.^{2,3} EBV infection could become dormant within host epithelial cells.⁴ This EBV in its dormant or latent phase would express various viral molecules that have been shown to be responsible for inducing carcinogenesis in nasopharyngeal cancer.⁵⁻⁸

Due to a tight association between EBV and nasopharyngeal cancer, EBV viral load have been proposed to be a biomarker that could possibly serve as a screening tool, guide treatment or inform prognosis. Detectable EBV viral load in plasma have been shown to be able to inform asymptomatic patient for greater risk of developing nasopharyngeal cancer.⁹ Furthermore, EBV viral load in plasma was found to be prognostic especially in predicting risk of distant recurrence.¹⁰ However, EBV viral load from local nasopharyngeal specimens have not been shown to be prognostic.¹¹

The EBV genotype from circulating plasma was found to be similar with the EBV genotype from tumor cells.¹² That finding indicating that EBV detected from plasma was very likely to be derived from EBV in tumor cells from the nasopharynx. Therefore, with the knowledge suggesting a prognostic role of plasma EBV viral load, the EBV DNA from tumor cells in nasopharynx was thought to be able to confer an even stronger prognostic value.

The previous study that found negative relationship between EBV virus from tumor cells and tumor burden or disease stage was thought due to the specimen collected from nasopharyngeal brushing might not represent the true EBV samples from tumor cells.¹¹ Therefore, a more accurate and representative design with EBV samples collected directly from microscopically confirmed tumor cells were used in this study to seek the role of EBV viral load in tumor cells.

Method

Study Design and Subject Recruitment

This study recruited subjects with microscopically confirmed nasopharyngeal carcinoma from nasopharynx biopsy. All subjects were 18 years and above. They all consented to be included in this study. All subjects underwent 3D imaging with either CT Scan or MRI for nasopharynx to assess initial pre-treatment tumor extension. The pre-treatment imaging utilized in this study was within 1 month of nasopharynx biopsy.

Sample Processing For Ebv Dna Quantification

The specimens were derived from a paraffin embedded tissue of those confirmed nasopharyngeal cancer patients. A 4 µm cut thickness of those paraffin embedded tissue were put into a slide. The slide then underwent standard hematoxylin-eosin staining. The stained slides were reviewed and the exact location of tumor cells were marked initially with a permanent marker by a senior pathologist. The marked slides were then re-marked again by carving the glass slides with a diamond pen. The permanently carved slides underwent pre-treatment for deparaffinization using xylene. The pre-treatment process of the slides was following QIAasympy® SP Protocol for tissue.

After pre-treatment, the DNA from the specimens was extracted and purified using QIAasympy DSP DNA Mini Kit. The DNA extracted was then quantified with a spectrophotometer following manufacturer

guideline. The DNA specimens were then diluted until reaching 100 ng DNA per ml of solution. Those homogenous DNA content from all the specimens were used for real time Polymerase Chain Reaction (RT-PCR) using artus® EBV RG PCR Kit for EBV DNA quantification.

Tumor Volume Determination

Tumor extensiveness in this study was referred to tumor volume. The 3D imaging done within 1 month of nasopharyngeal biopsy for all subjects were used for the basis of tumor volume determination. The tumor volume was determined by contouring the gross tumor locally in nasopharynx and regionally in cervical lymph nodes. The contouring was done using Eclipse™ software. The contouring was structured separately for gross tumor on local and regional to obtain local tumor volume and nodal tumor volume. The contours were performed by 2 radiation oncologists, independently. The final contours structures were discussed together to reach a consensus to determine the final structures. The volume for each structures were then recorded.

Statistical Analysis

A correlation test using Pearson's Correlation Test was performed between tumor volume and EBV viral load in tumor cells. The distribution for each numeric variable was determined using histogram. For the skewed distribution, if there was no correlation found, the data was re-arranged into logarithmic scale to obtain a normally distributed data. It was done whenever it was sensible and the basis of the data permit for conversion into logarithmic scale. A re-analysis of the correlation using Pearson's Correlation Test was done after normalization of data distribution to ascertain the presence or absence of the correlation.

Result

Subject Characteristics

Twenty-four subjects were included in this study. There was almost equal number of subjects under and up to age 50 and below 50. There were more males (75%) compared to females. All subjects were in locally advanced to advanced stage (stage III and above). There were 33.3% of subjects in advanced metastatic stage IVB. (see Table 1)

Table 1
Subject Characteristics

Characteristics	Number of Subjects (%)
Age	
≤ 50 years old	13 (54.2%)
> 50 years old	11 (45.8%)
Gender	
Male	18 (75%)
Female	6 (25%)
Stage*	
III	4 (16.7%)
IVA	12 (50%)
IVB	8 (33.3%)
Total	24 (100%)
* Based on AJCC Staging 8th Edition	

Relationship between Tumor Volume and EBV Viral Load in Tumor Cells

There was no correlation found between gross tumor volume at local nasopharynx with EBV viral load in tumor cells (see Fig. 1a). The median local tumor volume was $81.3 \text{ cm}^3 \pm 80 \text{ cm}^3$. The median EBV viral load in tumor cells was $95,644.8 \text{ copies}/100 \text{ ng of DNA} \pm 224,758.4 \text{ copies}/100 \text{ ng of DNA}$. Higher EBV viral load in tumor cells at local nasopharynx did not result in larger tumor at local nasopharynx.

There was also no correlation found between gross tumor volume at nodal or regional nasopharynx with EBV viral load in tumor cells (see Fig. 1b). The median nodal or regional tumor volume was $35.7 \text{ cm}^3 \pm 73.63 \text{ cm}^3$. Higher EBV viral load in tumor cells at local nasopharynx did not result in larger nor smaller tumor at nodal or regional nasopharynx.

The replication of EBV was following a geometric order, therefore the data distribution of EBV viral load was skewed if linear scale was used (see Fig. 2a). A converted scale from linear to logarithmic for EBV viral load in tumor cells have resulted in those data presented as normal distribution (see Fig. 2b). A re-analysis with EBV viral load in logarithmic scale was done.

There was also no correlation existed between both local tumor volume and nodal tumor volume with Log of EBV viral load in tumor cells from local nasopharynx (See Fig. 1c and 1d). The mean Log of EBV viral load in tumor cells from local nasopharynx was 4.94 Log copies/100 ng of DNA \pm 0.64 Log copies/100 ng of DNA.

Discussion

EBV viral load in tumor tissue from nasopharyngeal biopsy has been shown in our study not related to baseline tumor extensiveness. Even though EBV is presence in almost all nasopharyngeal cancer, the number of virus presence within the cancer cells did not translate into greater or smaller tumor sizes. This finding indicating that EBV virus replication within the host cells does not affect cancer phenotype.

There are evidence suggesting that expression of several EBV viral oncogenic genes are related to cancer development.^{4,13} These oncogenic proteins are probably the major driver of carcinogenesis, especially the proteins expressed by the latent EBV genes.⁴ In acute EBV infection, the lytic phase will ensue with expression of lytic genes. After lytic infection the virus will reside and become dormant within the epithelial or lymphocytes by expression of various latent genes. This latent genes such as Latent Membrane Protein 1 (LMP1) and Epstein-Barr nuclear antigen 1 (EBNA-1) expressed in latent phase of EBV infection were found to contribute to cancer development.⁴

The viral protein LMP1 was associated with inactivation of several important genes such as tumor suppressor genes within the host cells.^{4,14,15} The LMP1 inactivated tumor suppressor genes for instance Phosphatase and tensin homolog (PTEN) gene through the action of DNA methyltransferase 3b (DNMT3b).¹⁵ This DNMT3b resulted in PTEN CpG island methylation.¹⁵ Furthermore, the LMP1 expressed by EBV has also been shown to be able to methylate CDH-1 promoter region which eventually silencing E-cadherin gene. The cadherin is cell adhesion molecule in which deficient in this protein will promote cancer cells to easily metastasize.¹⁶

The EBNA-1 viral protein was associated with gene methylation process and genomic instability within the host genome.^{4,14} The gene profiling study has shown that EBNA-1 could bound to promoter sites of many host genes and resulted in upregulation and downregulation of specific genes.¹⁷ The presence of EBNA-1 was also related with elevated production of reactive oxygen species (ROS) within the host cells.¹⁸ This elevated ROS further increased the likelihood of genomic instability and DNA damage.¹⁸ In pre-clinical model, EBNA-1 expression was shown to be strongly associated with tumor growth.¹⁹ All these findings indicating that EBNA-1 is required at least in part for tumorigenesis.

Another EBV molecule that is also highly transcribed in latent EBV infection was Epstein-Barr Virus - encoded RNAs (EBER). The EBER is a small segment of RNA molecule that is not expressed into protein, but it plays a major role in facilitating the process of immune escape.⁴ The EBER can interfere with interferon stimulating gene, thereby blunting the immune response.²⁰ In concert with other EBV viral

proteins such as LMP1, the EBV could stimulate recruitment and activation of Treg into tumor microenvironment, therefore stimulating an even more permissive microenvironment for tumor growth.²¹

Based on all the findings above and the result of our study, the expression of these oncogenic viral genes is probably more likely to correlate with tumor progression rather than presence and the number of EBV virus alone. EBV viral load quantification in tumor tissue was probably useful to assist doubtful diagnosis of nasopharyngeal cancer, especially the endemic type with WHO type 3 histopathology.²² Quantification EBV DNA in tumor cells might not be able to confer valuable prognostic information. However, quantification of viral proteins or RNAs might be able to provide some prognostic clue.

Conclusion

EBV viral load in tumor tissue from nasopharyngeal biopsy did not correlate with baseline pre-treatment tumor extensiveness. The presence and number of virus in tumor cells was probably not much informative, except for confirming diagnosis of nasopharyngeal carcinoma. EBV viral molecules such as LMP1, EBNA-1, and EBER were probably more likely to confer prognostic information.

Declarations

Ethics approval and consent to participate

This study has obtained ethical approval by Board of Ethic Committee from Faculty of Medicine, Universitas Indonesia on 11 March 2019 with ethical approval number KET-229/UN2.F1/ETIK/PPM.00.02/2019. All subjects consented prior to their enrollment to this study.

Consent for publication

Not applicable

Availability of data and materials

Not applicable

Competing interests

The authors declare that they have no competing interests.

Funding

This study received a research grant from Universitas Indonesia. The funder has no role in specifying the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Authors' contributions

All authors have equal contributions. All authors read and approved the final manuscript.

Acknowledgement

We acknowledge, express gratitude and appreciation to QIAGEN Indonesia for generously provide this study with their QIAGEN kits for free.

Conflict of Interest

None

References

1. Cohen JI. Epstein-Barr virus infection. *N Engl J Med*. 2000 Aug;343(7):481–92.
2. Klein G, Giovanella BC, Lindahl T, Fialkow PJ, Singh S, Stehlin JS. Direct evidence for the presence of Epstein-Barr virus DNA and nuclear antigen in malignant epithelial cells from patients with poorly differentiated carcinoma of the nasopharynx. *Proc Natl Acad Sci U S A*. 1974 Dec;71(12):4737–41.
3. Fahraeus R, Fu HL, Ernberg I, Finke J, Rowe M, Klein G, et al. Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. *Int J cancer*. 1988 Sep;42(3):329–38.
4. Tsao SW, Tsang CM, Lo KW. Epstein-Barr virus infection and nasopharyngeal carcinoma. *Philos Trans R Soc London Ser B, Biol Sci*. 2017 Oct;372(1732).
5. Jain A, Chia WK, Toh HC. Immunotherapy for nasopharyngeal cancer-a review. *Chinese Clin Oncol*. 2016 Apr;5(2):22.
6. Gondhowiardjo SA, Adham M, Lisnawati L, Kodrat H, Tobing DL, Handoko H, et al. Current Immune-Related Molecular Approach in Combating Nasopharyngeal Cancer. *World J Oncol Vol 10, No 4-5, Oct 2019 [Internet]*. 2019 Sep 21; Available from: <https://www.wjon.org/index.php/wjon/article/view/1214/935> %3C
7. Gondhowiardjo S. Epstein-Barr virus latent membrane protein 1 (EBV-LMP1) and tumor proliferation rate as predictive factors of nasopharyngeal cancer (NPC) radiation response. *Gan To Kagaku Ryoho*. 2000 May;27 Suppl 2:323–31.
8. Young LS, Yap LF, Murray PG. Epstein – Barr virus: more than 50 years old and still providing surprises. *Nat Publ Gr [Internet]*. 2016;16(12):789–802. Available from: <http://dx.doi.org/10.1038/nrc.2016.92>
9. Chan KCA, Woo JKS, King A, Zee BCY, Lam WKJ, Chan SL, et al. Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer. *N Engl J Med*. 2017 Aug;377(6):513–22.
10. Shen T, Tang L-Q, Luo D-H, Chen Q-Y, Li P-J, Mai D-M, et al. Different prognostic values of plasma Epstein-Barr virus DNA and maximal standardized uptake value of 18F-FDG PET/CT for nasopharyngeal carcinoma patients with recurrence. *PLoS One*. 2015;10(4):e0122756.
11. Adham M, Greijer AE, Verkuijden SAWM, Juwana H, Fleig S, Rachmadi L, et al. Epstein-Barr Virus DNA Load in Nasopharyngeal Brushings and Whole Blood in Nasopharyngeal Carcinoma Patients before

- and after Treatment. *Clin Cancer Res.* 2013;2175–87.
12. Lin J-C, Wang W-Y, Chen KY, Wei Y-H, Liang W-M, Jan J-S, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. *N Engl J Med.* 2004 Jun;350(24):2461–70.
 13. Elgui de Oliveira D, Muller-Coan BG, Pagano JS. Viral Carcinogenesis Beyond Malignant Transformation: EBV in the Progression of Human Cancers. *Trends Microbiol.* 2016 Aug;24(8):649–64.
 14. Li L, Zhang Y, Guo B-B, Chan FKL, Tao Q. Oncogenic induction of cellular high CpG methylation by Epstein-Barr virus in malignant epithelial cells. *Chin J Cancer.* 2014 Dec;33(12):604–8.
 15. Peng H, Chen Y, Gong P, Cai L, Lyu X, Jiang Q, et al. Higher methylation intensity induced by EBV LMP1 via NF- κ B/DNMT3b signaling contributes to silencing of PTEN gene. *Oncotarget.* 2016 Jun;7(26):40025–37.
 16. Petrova YI, Schecterson L, Gumbiner BM. Roles for E-cadherin cell surface regulation in cancer. *Mol Biol Cell.* 2016 Nov;27(21):3233–44.
 17. Canaan A, Haviv I, Urban AE, Schulz VP, Hartman S, Zhang Z, et al. EBNA1 regulates cellular gene expression by binding cellular promoters. *Proc Natl Acad Sci U S A.* 2009 Dec;106(52):22421–6.
 18. Gruhne B, Sompallae R, Marescotti D, Kamranvar SA, Gastaldello S, Masucci MG. The Epstein-Barr virus nuclear antigen-1 promotes genomic instability via induction of reactive oxygen species. *Proc Natl Acad Sci U S A.* 2009 Feb;106(7):2313–8.
 19. Kaul R, Murakami M, Choudhuri T, Robertson ES. Epstein-Barr virus latent nuclear antigens can induce metastasis in a nude mouse model. *J Virol.* 2007 Oct;81(19):10352–61.
 20. Takada K. Role of EBER and BARF1 in nasopharyngeal carcinoma (NPC) tumorigenesis. *Semin Cancer Biol.* 2012 Apr;22(2):162–5.
 21. Baumforth KRN, Birgersdotter A, Reynolds GM, Wei W, Kapatai G, Flavell JR, et al. Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates Up-regulation of CCL20 and the migration of regulatory T cells. *Am J Pathol.* 2008 Jul;173(1):195–204.
 22. Zheng X-H, Lu L-X, Li X-Z, Jia W-H. Quantification of Epstein-Barr virus DNA load in nasopharyngeal brushing samples in the diagnosis of nasopharyngeal carcinoma in southern China. *Cancer Sci.* 2015 Sep;106(9):1196–201.

Figures




Figure 1: Scatterplot showing no correlation between a-b) EBV viral load in nasopharyngeal tumor tissue with a) local tumor volume, b) nodal tumor volume. c-d) Re-analysis of correlation using normalized distribution in logarithmic scale of EBV viral load in nasopharyngeal tumor tissue also showing no correlation with c) local tumor volume, d) nodal tumor volume

Figure 1

Scatterplot showing no correlation between a-b) EBV viral load in nasopharyngeal tumor tissue with a) local tumor volume, b) nodal tumor volume. c-d) Re-analysis of correlation using normalized distribution in logarithmic scale of EBV viral load in nasopharyngeal tumor tissue also showing no correlation with c) local tumor volume, d) nodal tumor volume




Figure 2: Histogram showing distribution of data for EBV viral load in tumor tissue from nasopharyngeal biopsy a) non-normal distribution with linear scale, b) normal distribution with logarithmic scale

Figure 2

Histogram showing distribution of data for EBV viral load in tumor tissue from nasopharyngeal biopsy a) non-normal distribution with linear scale, b) normal distribution with logarithmic scale